Business Description
Takeda Pharmaceutical Co Ltd
ISIN : JP3463000004
Share Class Description:
LTS:0RN3: Ordinary SharesTotal Employee Number:
47,455Compare
Compare
Traded in other countries / regions
4502.JapanTAK.USA0A87.UKTKD.GermanyTKD.AustriaTAKP34.BrazilTAK N.Mexico IPO Date
2017-02-24Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.65 | |||||
Debt-to-EBITDA | 7.66 | |||||
Interest Coverage | 4.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.04 | |||||
Beneish M-Score | -2.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.7 | |||||
3-Year EBITDA Growth Rate | -14.4 | |||||
3-Year EPS without NRI Growth Rate | -32.6 | |||||
3-Year FCF Growth Rate | 22.1 | |||||
3-Year Book Growth Rate | 4.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 68.99 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 0.62 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 311.1 | |||||
Days Sales Outstanding | 63.2 | |||||
Days Payable | 96.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 3.6 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 2.44 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.5 | |||||
Operating Margin % | 10.42 | |||||
Net Margin % | -3.54 | |||||
EBITDA Margin % | 13.97 | |||||
FCF Margin % | 23.03 | |||||
OCF Margin % | 23.03 | |||||
ROE % | -2.23 | |||||
ROA % | -1.09 | |||||
ROIC % | 3.44 | |||||
3-Year ROIIC % | -2.15 | |||||
ROC (Joel Greenblatt) % | -1.08 | |||||
ROCE % | -0.2 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 56.53 | |||||
Shiller PE Ratio | 41.47 | |||||
Price-to-Owner-Earnings | 62.43 | |||||
PS Ratio | 1.93 | |||||
PB Ratio | 1.17 | |||||
Price-to-Free-Cash-Flow | 8.59 | |||||
Price-to-Operating-Cash-Flow | 8.59 | |||||
EV-to-EBIT | -521.98 | |||||
EV-to-Forward-EBIT | 16.44 | |||||
EV-to-EBITDA | 20.6 | |||||
EV-to-Forward-EBITDA | 9.52 | |||||
EV-to-Revenue | 2.88 | |||||
EV-to-Forward-Revenue | 1.96 | |||||
EV-to-FCF | 12.8 | |||||
Price-to-GF-Value | 1.22 | |||||
Price-to-Projected-FCF | 0.72 | |||||
Price-to-Median-PS-Value | 1.1 | |||||
Earnings Yield (Greenblatt) % | -0.19 | |||||
FCF Yield % | 11.73 | |||||
Forward Rate of Return (Yacktman) % | 1.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Takeda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 25,492.121 | ||
| EPS (TTM) (€) | -0.586 | ||
| Beta | -0.0483 | ||
| 3-Year Sharpe Ratio | -54.59 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 2 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 37.59 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 37.59 - 37.59 | ||
| Shares Outstanding (Mil) | 1,596.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takeda Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takeda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2027-01-29 19:30 | In 171 days | ||
| Second quarter earnings conference call for 2026 | 2026-10-29 | In 77 days | ||
| Second quarter earnings results for 2026 | 2026-10-29 | In 77 days | ||
| JPY 102.000000 Cash Dividend | 2026-09-29 | In 47 days | ||
| First quarter earnings conference call for 2026 | 2026-07-30 | 37.59 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-07-30 | 37.59 (+0.00%) | ||
| General meeting for 2026 | 2026-06-24 10:00 | 37.59 (+0.00%) | ||
| Annual report for 2025 | 2026-06-17 | 37.59 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-05-13 06:00 | 37.59 (+0.00%) | ||
| JPY 100.000000 Cash Dividend | 2026-03-30 | 37.59 (+0.00%) |
Show
Entries
Takeda Pharmaceutical Co Ltd Frequently Asked Questions
What is Takeda Pharmaceutical Co Ltd(LTS:0RN3)'s stock price today?
The current price of LTS:0RN3 is €37.59. The 52 week high of LTS:0RN3 is €37.59 and 52 week low is €37.59.
When is next earnings date of Takeda Pharmaceutical Co Ltd(LTS:0RN3)?
The next earnings date of Takeda Pharmaceutical Co Ltd(LTS:0RN3) is 2026-10-29.
Does Takeda Pharmaceutical Co Ltd(LTS:0RN3) pay dividends? If so, how much?
Takeda Pharmaceutical Co Ltd(LTS:0RN3) does not pay dividend.
Press Release
Articles on Takeda Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers